Zobrazeno 1 - 10
of 41
pro vyhledávání: '"E. A. Lesovaya"'
Autor:
A. M. Scherbakov, T. I. Fetisov, D. V. Sorokin, V. Yu. Zinovieva, N. I. Moiseeva, L. A. Laletina, E. M. Kirilin, A. E. Manikaylo, L. Ya. Fomina, L. V. Mekheda, B. Yu. Bokhyan, E. A. Lesovaya, L. S. Trukhanova, T. G. Gor’kova, E. E. Antoshina, O. V. Morozova, K. I. Kirsanov, M. G. Yakubovskaya
Publikováno v:
Успехи молекулярной онкологии, Vol 9, Iss 2, Pp 58-65 (2022)
Introduction. The identification of predictive factors is a cornerstone task of modern oncology. The development of new targeted drugs determines the need for prediction of chemosensitivity of each patient to the prescribed therapy, in this regard, t
Externí odkaz:
https://doaj.org/article/71afdbbddba344529bf70f023fe79b06
Autor:
E. M. Zhidkova, D. D. Grigoreva, E. S. Lylova, V. P. Maksimova, G. R. Sagitova, G. I. Khayrieva, E. S. Trapeznikova, K. I. Kirsanov, M. G. Yakubovskaya, E. A. Lesovaya
Publikováno v:
Сибирский онкологический журнал, Vol 21, Iss 3, Pp 50-60 (2022)
Objective: screening of previously selected DDIT4 inhibitors by their ability to suppress basal and glucocorticoid-induced expression of this gene in breast cancer (BC) cells, as well as evaluation of antiproliferative and cytotoxic effects of the st
Externí odkaz:
https://doaj.org/article/0a86cb5f69c84ab6be5b86b5ee7b8015
Autor:
D. D. Grigorieva, E. M. Zhidkova, E. S. Lylova, D. V. Demina, K. I. Kirsanov, G. A. Belitsky, M. G. Yakubovskaya, E. A. Lesovaya
Publikováno v:
Успехи молекулярной онкологии, Vol 9, Iss 1, Pp 42-47 (2022)
Introduction. Glucocorticoids are often used in combination therapy for breast cancer as an adjuvant to increase therapeutic effects of the main cytotoxic drug and to reduce side effects of chemotherapy. However, glucocorticoids can cause serious com
Externí odkaz:
https://doaj.org/article/cae9ac30018c4ef68df2f5530867d10e
Autor:
D. D. Grigoreva, E. M. Zhidkova, E. S. Lylova, A. D. Enikeev, K. I. Kirsanov, G. A. Belitsky, M. G. Yakubovskaya, E. A. Lesovaya
Publikováno v:
Успехи молекулярной онкологии, Vol 9, Iss 4 (2022)
Introduction. Current chemotherapy of breast cancer has a wide range of disadvantages, in particular, the development of therapy-related infections and hormonal imbalance. Combination of main cytostatic with glucocorticoids allows to broaden its ther
Externí odkaz:
https://doaj.org/article/0fd1933c86234903a378d022060954b1
Publikováno v:
Успехи молекулярной онкологии, Vol 9, Iss 4 (2022)
Nanomaterials become more widespread in the different areas of human life, forming the new technosphere philosophy, in particular, new approaches for development and usage of these materials in everyday life, manufacture, medicine etc.The physicochem
Externí odkaz:
https://doaj.org/article/19e135e7eeb24ca58f954b0da993b2c8
Autor:
E. S. Lylova, A. V. Savinkova, E. M. Zhidkova, K. I. Kirsanov, M. G. Yakubovskaya, I. V. Budunova, E. A. Lesovaya
Publikováno v:
Сибирский онкологический журнал, Vol 19, Iss 6, Pp 73-81 (2020)
Glucocorticoids (GC ) have been an integral component of the treatment of leukemias and lymphomas for several decades. Specific cytotoxic effect of GC on transformed lymphoblasts mediates their use at the stage of the remission induction as well as c
Externí odkaz:
https://doaj.org/article/6ced8adb549c4e0883fcb15eaab92973
Autor:
V. P. Maksimova, J. V. Makus, O. G. Usalka, E. S. Lylova, P. E. Bugaeva, E. M. Zhidkova, D. A. Fedorov, O. P. Lizogub, E. A. Lesovaya, G. A. Belitsky, M. G. Yakubovskaya, K. I. Kirsanov
Publikováno v:
Сибирский онкологический журнал, Vol 19, Iss 4, Pp 67-78 (2020)
The purpose of the study was to analyze the ability of five antitumor drugs from the pharmaceutical group of protein kinase inhibitors (gefitinib, imatinib, pazopanib, ponatinib and enzastaurin) to reactivate the expression of the epigenetically sile
Externí odkaz:
https://doaj.org/article/5e44a769e15146daaabde60bf96de8c6
Autor:
K. I. Kirsanov, K. A. Kuzin, T. I. Fetisov, E. A. Lesovaya, G. A. Belitskiy, M. G. Yakubovskaya
Publikováno v:
Сибирский онкологический журнал, Vol 19, Iss 3, Pp 122-136 (2020)
The purpose of the study was to analyze the existing methodological approaches to the experimental testing of resistance to chemotherapy and assess the prospects for their further application.Material and Methods. We analyzed publications regarding t
Externí odkaz:
https://doaj.org/article/98b1ea96f5dc4b47bfe5bfd8784b0782
Autor:
T. I. Fetisov, K. I. Kirsanov, A. A. Borunova, M. N. Zatsepina, E. A. Lesovaya, T. N. Zabotina, G. A. Belitsky, M. G. Yakubovskaya
Publikováno v:
Успехи молекулярной онкологии, Vol 6, Iss 4, Pp 58-68 (2019)
Background. Curaxin CBL0137 is a novel non-genotoxic compound with anti-cancer activity based on CBL0137 ability of non-covalent interaction with DNA causing histone chaperone FACT relocation. Anti-cancer activity of this drug was demonstrated previo
Externí odkaz:
https://doaj.org/article/047f3e33a5274898981365fa2a000208
Autor:
K. A. Kuzin, T. I. Fetisov, R. I. Knyazev, L. Ya. Fomina, L. V. Meheda, E. A. Lesovaya, G. A. Belitsky, M. G. Yakubovskaya, K. I. Kirsanov
Publikováno v:
Успехи молекулярной онкологии, Vol 6, Iss 4, Pp 8-25 (2019)
Objectives: to provide a rationale for existing approaches for the evaluation of chemoresistance of ovarian cancer in vitro, to perform a comparative analysis of the methods and to assess the perspectives of their further application.Materials and me
Externí odkaz:
https://doaj.org/article/e1118a9a164e4969b74e1580da5ee8f1